NCT06802523View on ClinicalTrials.gov

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 21, 2026

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Acute Myeloid Leukemia
Interventions
RADIATION

Actinium Ac 225 Lintuzumab

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

DRUG

Decitabine and Cedazuridine

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

06520

RECRUITING

Yale University Cancer Center LAO, New Haven

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH